Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF OCTOBER 14, 2017 FBO #5804
SOLICITATION NOTICE

65 -- FDA 510(k) cleared T-cell medium for cell culture processing applications

Notice Date
10/12/2017
 
Notice Type
Presolicitation
 
NAICS
325413 — In-Vitro Diagnostic Substance Manufacturing
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, Clinical Center/Office of Purchasing & Contracts, 6707 Democracy Blvd, Suite 106, MSC 5480, Bethesda, Maryland, 20892-5480
 
ZIP Code
20892-5480
 
Solicitation Number
18-000029
 
Archive Date
11/11/2017
 
Point of Contact
Malinda Dehner, Phone: 301-594-6320, Barbara Taylor,
 
E-Mail Address
dehnerm@cc.nih.gov, Barbara_Taylor@nih.gov
(dehnerm@cc.nih.gov, Barbara_Taylor@nih.gov)
 
Small Business Set-Aside
N/A
 
Description
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. The National Institute of Health (NIH), Clinical Center (CC) intends to award a firm-fixed price purchase order to Life Technologies Corporation, a Thermo Fisher Scientific Company (Large Business) Carlsbad, CA 92008-7321 on a sole source basis to procure seventy (70) CTS TM AIM V® SFM that are used in the Cell Processing Section of the Department of Transfusion Medicine. Life Technologies Corporation, is the only known vendor that manufactures the GIBCO® CTS TM AIM V® SFM (Therapeutic Grade) defined, serum-free medium (SFM) for the proliferation and/or manipulation of T cells and dendritic cells manufactured in compliance with cGMP. This CTS TM AIM V® SFM is an FDA 510(k) cleared device intended for human ex-vivo tissue and cell culture processing applications. It contains L-glutamine, 50 µg/mL streptomycin sulfate, and 10 µg/mL gentamicin sulfate. The required media is used to expand autologous and allogenic Chimeric antigen Receptor (CAR) anti-CD10 cell products that are used to treat patients with B cell malignancies. Many of these patients have already begun a series of CAR cell treatments that would be interrupted if this were not available. The media must come from the same vendor so as to ensure consistency and not introduce a new media which could be responsible for potentially altering the results and adversely affect the processing of cells and a patient's treatment plan. This acquisition is being conducted under the authority of the FAR Subpart 13.106-1(b). Interested concerns capable of providing the same or similar products or services as described in this notice may submit a capability statement outlining their capabilities. Information received will be evaluated for the purpose of determining whether to conduct a competitive procurement. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Each response should include the following Business Information: a. DUNS. b. Company Name, address, POC, Phone and Email address c. Current GSA Schedules or NAICS codes appropriate to this Award. d. Type of Company (i.e., small business, 8(a), woman owned, hubZone, veteran owned, etc.) as validated in System For Award Management (SAM). All offerors must register on the SAM located at http://www.sam.gov/portal/SAM/#1 e. Capability Statement Comments to this announcement may be submitted to the Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Malinda Dehner, Contract Specialist, dehnerm@cc.nih.gov by the due date and time marked in this notice
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/CCOPC/18-000029/listing.html)
 
Place of Performance
Address: 9000 Rockville Pike, Bethesda, Maryland, 20892, United States
Zip Code: 20892
 
Record
SN04711709-W 20171014/171012230819-4a1ad34cce1484ab25142ea6c27f8875 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.